{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:17:29Z","timestamp":1648905449589},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T00:00:00Z","timestamp":1219795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00280-008-0816-5","type":"journal-article","created":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T09:38:18Z","timestamp":1219743498000},"page":"937-943","source":"Crossref","is-referenced-by-count":6,"title":["Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"Mario","family":"Campone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Blasinska-Morawiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tekiela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Koralewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Douville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Brandely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,27]]},"reference":[{"key":"816_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-006-0375-6","volume":"60","author":"J Bonneterre","year":"2007","unstructured":"Bonneterre J, Campone M, Koralewski P et al (2007) Vinorelbine\/docetaxel combination treatment of metastatic breast cancer: a phase I study. Cancer Chemother Pharmacol 60:365\u2013373","journal-title":"Cancer Chemother Pharmacol"},{"key":"816_CR2","first-page":"44","volume":"11","author":"S Matti","year":"1997","unstructured":"Matti S (1997) Aapro combination docetaxel-vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology 11:44\u201347","journal-title":"Oncology"},{"key":"816_CR3","first-page":"3","volume":"22","author":"MC Bissery","year":"1995","unstructured":"Bissery MC, Vrignaud P, Lavelle F (1995) Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Sem Oncol 22:3\u201316","journal-title":"Sem Oncol"},{"key":"816_CR4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","volume":"11","author":"P Fumoleau","year":"1993","unstructured":"Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first- line advanced breast cancer chemotherapy. J Clin Oncol 11:1245\u20131252","journal-title":"J Clin Oncol"},{"key":"816_CR5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/oxfordjournals.annonc.a059019","volume":"5","author":"J Garcia-Conde","year":"1994","unstructured":"Garcia-Conde J, Lluch A, Martin M et al (1994) Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854\u2013857","journal-title":"Ann Oncol"},{"key":"816_CR6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1994.12.2.336","volume":"12","author":"A Romero","year":"1994","unstructured":"Romero A, Rabinovich MG, Vallejo CT et al (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336\u2013341","journal-title":"J Clin Oncol"},{"key":"816_CR7","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.1995.13.11.2722","volume":"13","author":"BL Weber","year":"1995","unstructured":"Weber BL, Vogel C, Jones S et al (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722\u20132730","journal-title":"J Clin Oncol"},{"key":"816_CR8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000421-199510000-00006","volume":"18","author":"S Bruno","year":"1995","unstructured":"Bruno S, Puerto VL, Mickiewicz E et al (1995) Phase II trial of weekly i.v. vinorelbine as single agent in first-line advanced breast cancer chemotherapy The Latin-American experience. Am J Clin Oncol 18:392\u2013396","journal-title":"Am J Clin Oncol"},{"key":"816_CR9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/bjc.1994.435","volume":"70","author":"CJ Twelves","year":"1994","unstructured":"Twelves CJ, Dobbs NA, Curnow A et al (1994) A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990\u2013993","journal-title":"Br J Cancer"},{"key":"816_CR10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01806156","volume":"39","author":"M Terenziani","year":"1996","unstructured":"Terenziani M, Demicheli R, Brambilla C et al (1996) Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer: results from a phase II study. Breast Cancer Res Treat 39:285\u2013291","journal-title":"Breast Cancer Res Treat"},{"key":"816_CR11","doi-asserted-by":"crossref","unstructured":"Trillet-Lenoir V, Sommer H, Delozier T et al (2004) Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II studies. Eur J Cancer, 2:3 abst 279","DOI":"10.1016\/S1359-6349(04)90882-8"},{"key":"816_CR12","first-page":"35","volume":"21","author":"G Freyer","year":"2003","unstructured":"Freyer G, Delozier T, Lichinister M et al (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35\u201340","journal-title":"J Clin Oncol"},{"key":"816_CR13","doi-asserted-by":"crossref","unstructured":"Gridelli C, Parlier Y, Brandely M et al (2003) Oral chemotherapy and upper gastro-intestinal tolerance improvement of nausea and vomiting in non-small cell lung cancer patients treated with oral navelbine and standard antiemetic prophylaxis. Eur J Cancer 1:5 abst 801","DOI":"10.1016\/S1359-6349(03)90826-3"},{"key":"816_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110\u2013115","journal-title":"J Clin Oncol"},{"key":"816_CR15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","volume":"12","author":"M Marty","year":"2001","unstructured":"Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643\u20131649","journal-title":"Ann Oncol"},{"key":"816_CR16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","volume":"328","author":"PA Pizzo","year":"1993","unstructured":"Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. New Eng J Med 328:1323\u20131332","journal-title":"New Eng J Med"},{"key":"816_CR17","unstructured":"De Paz L, Lluch A, Martin M et al (1999) A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC) Proc Am soc Clin Oncol, 18:119a abst 452"},{"key":"816_CR18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/JCO.2001.19.3.621","volume":"19","author":"GV Kornek","year":"2001","unstructured":"Kornek GV, Ulrich-Pur H, Penz M et al (2001) Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 19:621\u2013627","journal-title":"J Clin Oncol"},{"key":"816_CR19","unstructured":"Pectasides D, Papadimitriou L, Aravantinos G et al (2000) Docetaxel (Doc) and Navelbine (NVB) as first line chemotherapy (CT) in advanced breast cancer (ABC): a phase II study of Hellenic Cooperative Oncology Group Proc Am Soc Clin Oncol, 19:112a abst 435"},{"key":"816_CR20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1020273502426","volume":"76","author":"J Rodriguez","year":"2002","unstructured":"Rodriguez J, Calvo E, Cortes J et al (2002) Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study. Breast cancer Res Treat 76:47\u201356","journal-title":"Breast cancer Res Treat"},{"key":"816_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00280-002-0548-x","volume":"51","author":"M Vassilomanolakis","year":"2003","unstructured":"Vassilomanolakis M, Koumakers G, Drufakou S et al (2003) Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 51:179\u2013183","journal-title":"Cancer Chemother Pharmacol"},{"key":"816_CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3816\/CBC.2004.n.017","volume":"5","author":"J Mayodorma","year":"2004","unstructured":"Mayodorma J, Milla A, Morales S et al (2004) Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. Clin Breast Cancer 5:131\u2013135","journal-title":"Clin Breast Cancer"},{"key":"816_CR23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1023\/A:1011133410652","volume":"12","author":"M Campone","year":"2001","unstructured":"Campone M, Fumoleau P, Delecroix V et al (2001) Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann Oncol 12:909\u2013918","journal-title":"Ann Oncol"},{"key":"816_CR24","unstructured":"Fumoleau P, Campone M, Tekiela A et al (2003) Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC) Proc 5th Milan breast cancer conf 86 abst 64"},{"key":"816_CR25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-007-0605-6","volume":"62","author":"R Addeo","year":"2007","unstructured":"Addeo R, Faiola V, Guarrasi R et al (2007) Liposomal pegylated doxorubicin plus vinorelbine combination as first line chemotherapy for metastatic breast cancer in elderly women\u00a0\u2265\u00a065\u00a0years of age. Cancer Chemother Pharmacol 62:285\u2013292","journal-title":"Cancer Chemother Pharmacol"},{"key":"816_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1081\/CNV-120000363","volume":"20","author":"N Ibrahim","year":"2002","unstructured":"Ibrahim N, Rahman Z, Valero V et al (2002) Phase I study of vinorelbine and docetaxel with granulocyte colony stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 20:29\u201337","journal-title":"Cancer Invest"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0816-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T22:55:05Z","timestamp":1588892105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,27]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0816-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,27]]}}}